MHM Magazine

rest • restore • revive Aspen Time to reach peak plasma concentration is 84 minutes and elimination half-life is 2,5 hours, therefore suited to the person who Doxylamine succinate 25 mg For the alleviation of insomnia Peak plasma levels occur 1,25 hours after oral administration, therefore suited to the patients who 10 mg / 20 mg Elimination half-life is 5 hours, therefore suited to the person who S5 ZOLNOXS 10 mg Tablets . Reg. No.: 36/2.2/0328. Each film-coated tablet contains 10 mg zolpidem tartrate. S5 ALCHERA Tablets . Reg. No.: 33/2.2/0029; Each tablet contains 7,5 mg zopiclone. S2 SOMNIL Tablet . Reg. No.: Q/2.2/186. Each tablet contains 25 mg of doxylamine succinate. S5 NORMISON 10 mg . Reg. No.: L/2.2/125. Each soft gelatin capsule contains 10 mg of temazepam. S5 NORMISON 20 mg . Reg. No.: M/2.2/205. Each soft gelatin capsule contains 20 mg of temazepam. For full prescribing information refer to the professional information approved by the medicines regulatory authority (ZOLNOXS 10 mg Tablets 10/2020, ALCHERA Tablets 10/2000, SOMNIL Tablet 02/1994, NORMISON 12/1989). Trademarks are owned by or licensed to the Aspen Group of companies. © 2021 Aspen Group of companies or its licensor. All rights reserved. Pharmacare Limited. Co. Reg. No.: 1898/000252/06. Healthcare Park, Woodlands Drive, Woodmead, 2191. ZAR-DOX-08-21-00006 09/2021 CAN’T FALL ASLEEP OR REQUIRE A PRE-MED 3 CAN’T STAY ASLEEP 1,2 CAN’T FALL ASLEEP 1,2 COUNTING SHEEP References: 1. Nakajima T, Sasaki T, Nakagome K, Takazawa S, Ikebuche E, Ito Y. 2000. Comparison of the effects of zolpidem and zopiclone on nocturnal sleep and sleep latency in the morning. A cross-over study in healthy young volunteers. Life Sciences ; 67:81-90. 2. Drover DR. Comparative Pharmacokinetics and Pharmacodynamics of Short-Acting Hypnosedatives. Zaleplon, Zolpidem and Zopiclone. Clin Pharmacokinet. 2004;43(4):227-238. 3. Holm KJ, Goa KL. Zolpidem: An Update of its Pharmacology, Therapeutic Efficacy and Tolerability in the Treatment of Insomnia. Drugs 2000;59(4):865-889. rest • restore • revive Aspen Time to reach peak plasma concentration is 84 minutes and elimination half-life is 2,5 hours, therefore suited to the person who Doxylamine succinate 25 mg For the alleviation of insomnia Peak plasma levels occur 1,25 hours after oral administration, therefore suited to the patients who 10 mg / 20 mg Elimination half-life is 5 hours, therefore suited to the person who S5 ZOLNOXS 10 mg Tablets . Reg. No.: 36/2.2/0328. Each film-coated tablet contains 10 mg zolpidem tartrate. S5 ALCHERA Tablets . Reg. No.: 33/2.2/0029; Each tablet contains 7,5 mg zopiclone. S2 SOMNIL Tablet . Reg. No.: Q/2.2/186. Each tablet contains 25 mg of doxylamine succinate. S5 NORMISON 10 mg . Reg. No.: L/2.2/125. Each soft gelatin capsule contains 10 mg of temazepam. S5 NORMISON 20 mg . Reg. No.: M/2.2/205. Each soft gelatin capsule contains 20 mg of temazepam. For full prescribing information refer to the professional information approved by the medicines regulatory authority (ZOLNOXS 10 mg Tablets 10/2020, ALCHERA Tablets 10/2000, SOMNIL Tablet 02/1994, NORMISON 12/1989). Trademarks are owned by or licensed to the Aspen Group of companies. © 2021 Aspen Group of companies or its licensor. All rights reserved. Pharmacare Limited. Co. Reg. No.: 1898/000252/06. Healthcare Park, Woodlands Drive, Woodmead, 2191. ZAR-DOX-08-21-00006 09/2021 CAN’T FALL ASLEEP OR REQUIRE A PRE-MED 3 CAN’T STAY ASLEEP 1,2 CAN’T FALL ASLEEP 1,2 COUNTING SHEEP References: 1. Nakajima T, Sasaki T, Nakagome K, Takazawa S, Ikebuche E, Ito Y. 2000. Comparison of the effects of zolpidem and zopiclone on nocturnal sleep and sleep latency in the morning. A cross-over study in healthy young volunteers. Life Sciences ; 67:81-90. 2. Drover DR. Comparative Pharmacokinetics and Pharmacodynamics of Short-Acting Hypnosedatives. Zaleplon, Zolpidem and Zopiclone. Clin Pharmacokinet. 2004;43(4):227-238. 3. Holm KJ, Goa KL. Zolpidem: An Update of its Pharmacology, Therapeutic Efficacy and Tolerability in the Treatment of Insomnia. Drugs 2000;59(4):865-889.